Company registration number 03983078 (England and Wales)
MY PHARMACY LIMITED
FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
MY PHARMACY LIMITED
COMPANY INFORMATION
Directors
Mr A M Mansour
Mr M H Mansour
Company number
03983078
Registered office
9 Lydford Road
England
NW2 5QY
Auditor
Xeinadin Audit Ltd
Suite 13, Leavesden Park
5 Hercules Way
Watford
Hertfordshire
WD25 7GS
MY PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
MY PHARMACY LIMITED
BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 1 -
31 March 2025
30 April 2024
Notes
£
£
£
£
Intangible assets
-
0
-
0
Current assets
Debtors
3
289,104
323,654
Cash at bank and in hand
1,410
81,582
290,514
405,236
Creditors: amounts falling due within one year
4
(1,549)
(114,419)
Net current assets
288,965
290,817
Capital and reserves
Called up share capital
2
2
Profit and loss reserves
288,963
290,815
Total equity
288,965
290,817

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 23 June 2026 and are signed on its behalf by:
Mr A M Mansour
Director
Company registration number 03983078 (England and Wales)
MY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2025
- 2 -
1
Accounting policies
Company information

My Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is 9 Lydford Road, England, NW2 5QY.

1.1
Reporting period

The current financial statements cover an 11-month period ended 31 March 2025 due to a change in the Company's accounting reference date to align with the Group's year end. The comparative figures relate to the 12-month period ended 30 April 2024 and are not directly comparable.

1.2
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.3
Going concern

The company ceased trading in March 2024 and its trade was transferred to another company within the Group. The directors have therefore concluded that the company is no longer a going concern and the financial statements have been prepared on break-up basis.true

1.4
Revenue

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

MY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 3 -
1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

1.7
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.9
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.10

Related party exemption

The company has taken advantage of the exemption, under the terms of Financial Reporting Standard 102 1A. The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

MY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 MARCH 2025
- 4 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the period was:

2025
2024
Number
Number
Total
0
0
3
Debtors
2025
2024
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
289,104
312,721
Other debtors
-
0
10,933
289,104
323,654
4
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
-
0
93,707
Taxation and social security
1,549
966
Other creditors
-
0
19,746
1,549
114,419
5
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 March 2025 and of its loss for the period then ended;

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- have been prepared in accordance with the requirements of the Companies Act 2006.

Senior Statutory Auditor:
Andrew Thomas
Statutory Auditor:
Xeinadin Audit Ltd
Date of audit report:
23 June 2026
MY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 MARCH 2025
- 5 -
6
Parent company

Canary Trading Company Limited, a company incorporated in England & Wales, i s the ultimate parent company.

2025-03-31 2024-05-01 false false false 23 June 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr A M Mansour Mr M H Mansour 03983078 2024-05-01 2025-03-31 03983078 bus:Director1 2024-05-01 2025-03-31 03983078 bus:Director2 2024-05-01 2025-03-31 03983078 bus:RegisteredOffice 2024-05-01 2025-03-31 03983078 2025-03-31 03983078 2024-04-30 03983078 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 03983078 core:CurrentFinancialInstruments core:WithinOneYear 2024-04-30 03983078 core:CurrentFinancialInstruments 2025-03-31 03983078 core:CurrentFinancialInstruments 2024-04-30 03983078 core:ShareCapital 2025-03-31 03983078 core:ShareCapital 2024-04-30 03983078 core:RetainedEarningsAccumulatedLosses 2025-03-31 03983078 core:RetainedEarningsAccumulatedLosses 2024-04-30 03983078 2023-05-01 2024-04-30 03983078 bus:PrivateLimitedCompanyLtd 2024-05-01 2025-03-31 03983078 bus:SmallCompaniesRegimeForAccounts 2024-05-01 2025-03-31 03983078 bus:FRS102 2024-05-01 2025-03-31 03983078 bus:Audited 2024-05-01 2025-03-31 03983078 bus:FullAccounts 2024-05-01 2025-03-31 xbrli:pure xbrli:shares iso4217:GBP